Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (593)	8/1/2000 4:45:02 PM
From: Toni Wheeler	Respond to of 743

re: GNLB Something is 'cooking' with Genelabs lately; today, particularly: GNLB: GENELABS TECHNO Time Last Change 15:58 3 7/8 + 7/16 Bid(Size) Ask(Size) Volume 3.66(1) 3 7/8(30) 347,200 Open High Low 3 7/16 3.97 3 3/8 #Trades Avg Size Last Size 476 729 800 52WkHi 52WkLo Last Tics 16 1/2 1 1/2 -+-+ GNLB - GENELABS TECHNOLOGIES Exchange: Nasdaq NM Delay: at least 15 minutes Last Price: 3 7/8 at 15:58 EDT Change: Up 7/16 (+12.73%) High: 3 31/32 at 13:19 EDT Low: 3 3/8 Open: 3 7/16 Previous Close: 3 7/16 on 7/31 Volume: 347,200 30-Day Avg. Volume: 393,000 Shares Outstanding: 40,795,000 Market Cap.: 158,080,625 52-Week High: 16 1/2 52-Week Low: 1 1/2 Beta: 0.44 Some nice DD has been posted on the Raging Bull GNLB board. It appears the company has filed with FDA proving that DHEA should not be classified as a 'dietary supplement' and requesting a ruling for their request: <<<SUMMARY: The Food and Drug Administration (“FDA”) has received information to suggest that products containing dehydroepiandrosterone (“DHEA”) may not legally be marketed as “dietary supplements” under the Federal Food, Drug, and Cosmetic Act (“FFDCA” or “the Act”). All interested persons are hereby notified of the process FDA will use to determine whether DHEA-containing products may legally be marketed as “dietary supplements” under the Act. ... <<<...FDA has determined that the evidence submitted by Genelabs establishes aprima facie case that DHEA is excluded from the definition of “dietary supplement” under Section 201 (ff)(3)(B)(ii) of the Act. ...>>> The speculated timeframe is this week for the decision. If the ruling is in their favor, I would assume the way would be cleared for fast-track approval of their GL701 product for SLE treatment. If more info is desired, check out the RB thread for some compelling articles and opinions. I believe Yahoo! also has some astute posters. My best, T.